Company news
Bioventus Inc. (NASDAQ:BVS) news
Every Bioventus Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Bioventus to Report Second Quarter of Fiscal Year 2026 Financial Results on August 5, 2026
July 29, 2026
Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference
June 2, 2026
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Pro...
April 30, 2026
Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026
April 28, 2026
Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results
March 5, 2026
Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026
February 24, 2026
Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
Bioventus Reports Third Quarter Financial Results
November 4, 2025
Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025
October 28, 2025
Bioventus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
September 3, 2025
Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference
August 7, 2025
Bioventus Reports Second Quarter Financial Results
August 6, 2025
Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity
August 4, 2025
Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products
July 30, 2025
Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025
July 29, 2025
Bioventus Reports First Quarter Financial Results
May 6, 2025
Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025
April 28, 2025
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results
March 11, 2025
Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025
February 28, 2025
Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
January 2, 2025
Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024
October 29, 2024
Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
October 1, 2024
Bioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference
August 7, 2024
Bioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024
July 30, 2024
Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024
April 29, 2024
Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results
March 12, 2024
Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024
March 4, 2024
Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole
January 12, 2024
Bioventus Names Robert Claypoole as President and Chief Executive Officer
December 19, 2023
Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis
December 6, 2023
Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance
November 7, 2023
Bioventus to Report Third Quarter of Fiscal Year 2023 Financial Results on November 7, 2023
October 31, 2023
Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance
August 8, 2023
Bioventus to Report Second Quarter of Fiscal Year 2023 Financial Results on August 8, 2023
August 1, 2023
Bioventus Completes Divestiture of its Wound Business
May 23, 2023
Bioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023
May 15, 2023
Bioventus Reschedules Earnings Call to May 16, 2023; Files for Extension to File Form 10-Q for the Period Ended April 1, 2023
May 11, 2023
Bioventus Announces Divestiture of its Wound Business
May 10, 2023
Bioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023
May 3, 2023
Bioventus Announces CEO Leadership Change
April 5, 2023
Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
March 31, 2023
Bioventus Reschedules Reporting of Fourth Quarter Fiscal Year 2022 Financial Results to March 31, 2023
March 29, 2023
Bioventus to Report Fourth Quarter of Fiscal Year 2022 Financial Results on March 30, 2023
March 16, 2023
Bioventus Enters into Settlement Agreement to Preserve Maximum Optionality – Up To $350mm of Potential Liability Reduction and a Release ...
February 28, 2023
Bioventus to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 4, 2023
Bioventus Issues Revised Third Quarter Results; Updates Full-Year 2022 Financial Guidance
November 21, 2022
Bioventus Files for Extension to File Form 10-Q for the Period Ended October 1, 2022
November 16, 2022
Bioventus Reports Third Quarter Results; Updates Full-Year 2022 Financial Guidance
November 8, 2022
Bioventus to Report Third Quarter of Fiscal Year 2022 Financial Results on November 8, 2022
October 31, 2022